1stOncology™: Cancer Intelligence Service – Page 15177 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

DGAP-News: EVOTEC TO ATTEND UPCOMING INVESTOR CONFERENCES

On November 9, 2017 Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) reported that its management will be presenting at the Jefferies 2017 London Healthcare Conference in London, UK, at the German Equity Forum in Frankfurt, Germany, and at the Annual Berenberg European Conference in Surrey, UK, and will be attending DZ BANK Equity Conference in Frankfurt, Germany, and dbAccess Pharmaceutical and Healthcare Corporate Day in London, UK (Press release, Evotec, NOV 9, 2017, View Source [SID1234521864]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Jefferies 2017 London Healthcare Conference, London, UK
Date: Thursday, 16 November 2017, 11.20 am GMT (12.20 pm CET, 06.20 am EST)
Webcast: Click here for the webcast
Venue: London, UK
Attendee: Dr Werner Lanthaler, Chief Executive Officer of Evotec AG

DZ BANK Equity Conference, Frankfurt, Germany
Date: Wednesday, 22 November 2017
Venue: Frankfurt, Germany
Attendee: Dr Werner Lanthaler, Chief Executive Officer of Evotec AG

German Equity Forum, Frankfurt, Germany
Date: Monday, 27 November 2017, 11.30 am CET (10.30 am GMT, 05.30 am EST)
Venue: Frankfurt, Germany
Attendee: Dr Werner Lanthaler, Chief Executive Officer of Evotec AG

dbAccess Pharmaceutical and Healthcare Corporate Day, London, UK
Date: Thursday, 30 November 2017
Venue: London, UK
Attendee: Enno Spillner, Chief Financial Officer of Evotec AG

Annual Berenberg European Conference, Surrey, UK
Date: Wednesday, 06 December 2017, 09.45 am GMT (10.45 am CET, 04.45 am EST)
Venue: Surrey, UK
Attendee: Dr Werner Lanthaler, Chief Executive Officer of Evotec AG

Pfenex Inc. to Present at the Jefferies 2017 London Healthcare Conference

On November 9, 2017 Pfenex Inc. (NYSE AMERICAN: PFNX), reported that it will be presenting at the Jefferies 2017 London Healthcare Conference on Wednesday, November 15th at 12:40 pm GMT / 7:40 pm ET (Press release, Pfenex, NOV 9, 2017, View Source2017-11-09-Pfenex-Inc-to-Present-at-the-Jefferies-2017-London-Healthcare-Conference" target="_blank" title="View Source2017-11-09-Pfenex-Inc-to-Present-at-the-Jefferies-2017-London-Healthcare-Conference" rel="nofollow">View Source [SID1234521896]). The presentation will be webcast and available for replay in the Investors Section of Pfenex’s website at www.pfenex.com.

Pfenex investors and others should note that we announce material information to the public about the Company through a variety of means, including our website (View Source), our investor relations website (View Source), press releases, SEC filings, public conference calls, corporate Twitter account (View Source), Facebook page (View Source), and LinkedIn page (View Source) in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.

NEW EFTILAGIMOD ALPHA (LAG-3Ig or IMP321) DATA FOR PRESENTATION AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 2017 ANNUAL MEETING

On November 9, 2017 Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ("Prima") reported the presentation of new data from its TACTI-mel Phase I clinical trial in Australia investigating the use of eftilagimod alpha (LAG-3Ig or IMP321), the Company’s lead product candidate, in combination with pembrolizumab (KEYTRUDA) in unresectable or metastatic melanoma patients (Press release, Prima Biomed, NOV 9, 2017, View Source [SID1234521897]).

The data will be presented in the poster titled "Pushing the accelerator and releasing the brake: testing the soluble LAG-3 protein (IMP321), an antigen presenting cell activator, together with pembrolizumab in unresectable or metastatic melanoma" (Poster Number P259) for the first time at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2017 Annual Meeting, to be held on November 10-12, 2017 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland. Eftilagimod alpha, which is a soluble LAG-3Ig fusion protein, is an APC activator boosting T cell responses.

"The data to be presented at the SITC (Free SITC Whitepaper) meeting is very encouraging and demonstrates that anti-tumor activity was observed in patients following the administration of eftilagimod alpha in combination with pembrolizumab. Furthermore, it is important to note that prior to coming into this study, these patients were treated with pembrolizumab monotherapy and did not achieve a meaningful therapeutic benefit from this treatment," stated Dr. Frédéric Triebel, Prima’s Chief Scientific Officer and Medical Officer.
The patients eligible to participate in the TACTI-mel Phase 1 clinical trial are those that have either had a suboptimal response or had disease progression with KEYTRUDA monotherapy as a first-line of treatment. 12 patients from the first two cohorts of the trial were treated with 1 and 6mg doses of eftilagimod alpha respectively. The third cohort of patients, being treated with 30 mg doses, is ongoing.

Dr. Frédéric Triebel further commented, "The data also supports the hypothesis that there is a therapeutic synergy when administering an APC activator, which enhances anti-tumor T cell production, in combination with a checkpoint inhibitor, which releases the brake on the T cells."

The presentation at the SITC (Free SITC Whitepaper) conference includes the following results:

• Combination of eftilagimod alpha (1 and 6 mg) and pembrolizumab in advanced metastatic melanoma patients is safe and well tolerated;
• Anti-tumor activity (tumor reduction) was observed in 7/12 patients (58 %) in this study; prior to the study all of these patients either had a suboptimal response or had disease progression when treated with the pembrolizumab monotherapy;

• Data presented supports the hypothesis that combining an APC activator (IMP321) with a checkpoint inhibitor (pembrolizumab) results in a therapeutic synergy and a potential clinical benefit over a checkpoint inhibitor monotherapy;

• Data presented supports further investigation of IMP321 in combination with PD-1/ PD-L1 checkpoint inhibitors in different tumor types.

Marc Voigt, Prima’s Chief Executive Officer, added, "We believe the positive data, taken together with the excellent safety profile of eftilagimod alpha and data from our ongoing clinical trial in metastatic breast cancer, further validate the therapeutic utility of modulating the LAG-3 immune control mechanism. We are very pleased with the clinical progress of eftilagimod alpha and look forward to presenting additional data from the TACTI-mel clinical trial and exploring the potential therapeutic benefit of combining it with other checkpoint inhibitors in other solid tumors."
A copy of this SITC (Free SITC Whitepaper) poster presentation is available on Prima’s website in the Presentations section of the Investors tab at View Source

Supernus to Present at Three November Healthcare Conferences

On November 9, 2017 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, reported that the Company’s management will present an overview and update for the Company, and host investor meetings at the following three conferences (Press release, Supernus, NOV 9, 2017, View Source [SID1234521905]):

Stifel 2017 Healthcare Conference
Date: Tuesday, November 14, 2017
Time: 11:45 a.m. EST
Place: Lotte New York Palace Hotel, New York

Jefferies 2017 London Healthcare Conference
Date: Thursday, November 16, 2017
Time: 4:40 p.m. GMT (11:40 a.m. EST)
Place: Waldorf Hilton, London, U.K.

Piper Jaffray 29th Annual Healthcare Conference
Date: Wednesday, November 29, 2017
Time: 8:00 a.m. EST
Place: Lotte New York Palace Hotel, New York

Investors interested in arranging a meeting with the Company’s management during these conferences should contact the conference coordinator.

A live webcast of the presentation can be accessed by visiting ‘Events & Presentations’ in the Investors Section on the Company’s website at www.supernus.com. An archived replay of these webcasts will be available for 60 days on the Company’s website after each conference.

TRACON Pharmaceuticals Presents Updated Data from Phase 1b/2 Study of TRC105 and Votrient® in Patients with Soft Tissue Sarcoma Including Angiosarcoma

On November 9, 2017 TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, reported updated data from the Company’s Phase 1b/2 study of TRC105 and Votrient (pazopanib) in patients with angiosarcoma at the Connective Tissue Oncology Society (CTOS) annual meeting taking place in Maui, Hawaii (Press release, Tracon Pharmaceuticals, NOV 9, 2017, View Source;p=RssLanding&cat=news&id=2315809 [SID1234521907]).

In poster presentation 2804349 entitled, "Every Other Week Dosing of TRC105 (Endoglin Antibody) in Combination with Pazopanib in Patients with Advanced Soft Tissue Sarcoma," updated data were presented from 18 angiosarcoma patients treated with the combination of TRC105 and Votrient, and an additional cohort of six soft tissue sarcoma patients treated with a hybrid dosing schedule of TRC105 and Votrient. Key results included:

TRC105 target concentrations previously shown to saturate endoglin receptors were achieved continuously using a TRC105 hybrid dosing schedule of 10 mg/kg weekly for four weeks followed by 15 mg/kg every other week.
Median progression-free survival (PFS) was 7.8 months in 13 VEGF inhibitor naïve angiosarcoma patients treated with the combination of TRC105 and Votrient using either 10 mg/kg weekly dosing or the hybrid dosing schedule of TRC105. This compares favorably to the median PFS of 3 months reported in a retrospective study of single agent Votrient in patients with angiosarcoma.
In the 17 patients who received prior treatment of metastatic disease, treatment duration on TRC105 and Votrient exceeded the duration of the most recent prior therapy in 7 of 12 VEGF naïve angiosarcoma patients and 2 of 5 patients who received a prior VEGF inhibitor as part of their most recent prior therapy.
Treatment with the combination of TRC105 and Votrient continued to be well-tolerated and allowed for dosing of the combination for more than two years in patients who experienced complete responses to treatment.

"The combination of TRC105 and Votrient continues to demonstrate the potential to deliver meaningful benefits to angiosarcoma patients. We continue to achieve important progress with the clinical development of this compelling product candidate, as our pivotal Phase 3 TAPPAS trial is now open at more than 20 sites in the U.S., and European sites are expected to open by year-end," said Charles Theuer, M.D., Ph.D., President and CEO of TRACON. "We also continue to evaluate every other week dosing of TRC105 in other indications, including lung and liver cancers."

The poster is available on TRACON’s website at www.traconpharma.com.

About Carotuximab (TRC105)

TRC105 is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in a pivotal Phase 3 trial in angiosarcoma and multiple Phase 2 clinical trials, in combination with VEGF inhibitors. TRC105 has received orphan designation for the treatment of soft tissue sarcoma in both the U.S. and EU. The ophthalmic formulation of TRC105, DE-122, is currently in a randomized Phase 2 trial for patients with wet AMD. For more information about the clinical trials, please visit TRACON’s website at www.traconpharma.com/clinical_trials.php.